Chris Klein

Chris Klein, Esq., joined Shionogi Inc. in May 2023 as Senior Vice President and General Counsel.

Mr. Klein brings to Shionogi Inc. more than thirty years of legal and compliance leadership in the biotechnology and pharmaceutical industry. His diverse expertise includes corporate governance, intellectual property procurement and litigation, compliance and reorganizations.

Mr. Klein joins Shionogi Inc. from RVL Pharmaceuticals, where he served as General Counsel and Secretary. He has also served as General Counsel at Fougera Pharmaceuticals through its acquisition by Sandoz, held the role of Deputy General Counsel at King Pharmaceuticals through its acquisition by Pfizer Inc., and has held positions of increasing responsibility at Bristol-Myers Squibb where he oversaw biotechnology intellectual property and licensing.

Mr. Klein received his J.D. from Fordham University School of Law in New York.